| News Releases |
SWOG S0226 finds anastrozole/fulvestrant combo can extend PFS and OS for ER+ breast cancer patients
[Dec. 7, 2011]
|
Post-menopausal women with hormone receptor-positive metastatic breast cancer may have a new treatment option that could lengthen their lives, according to results of SWOG study S0226, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.
The combination of the two anti-estrogen drugs anastrozole and fulvestrant extended the median survival time of women with breast cancer by more than six months compared to those who underwent standard treatment with anastrozole alone (47.7 months vs 41.3 months). The combination therapy also lengthened the median time to disease progression (15 months vs 13.5 months).
Lead study coordinator Rita Mehta, M.D., of the University of California, Irvine Medical Center says the results of the phase III trial are particularly exciting because “these patients have not had a new treatment that gave them an overall survival benefit in more than a decade.”
|
| |
SWOG SELECT study shows increased prostate cancer risk from vitamin E supplements
[Oct. 11, 2011]
|
An updated review of data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
concluded that men who took 400 international units of vitamin E daily had more prostate
cancers than men who took a placebo. Results are published in the October 12, 2011, JAMA.
SELECT participants can learn more from the SELECT website.
[Download larger version of graphic.]
|
| |
3-drug H. pylori regimen superior in Latin America study
[Jul. 19, 2011]
|
Clinical trials in Europe and Asia were thought to have pinpointed the best treatment regimen to eradicate the H. pylori bug, an important cause of peptic ulcers and gastric cancer. New results from a large SWOG study in Latin America turn those findings on their head, suggesting different populations need different therapies.
|
| |
Group chairs agree to guiding principles for transforming cooperative groups
[May. 19, 2011]
|
|
SWOG has joined with the other cooperative groups in formulating a consensus opinion on upcoming changes to the National Cancer Institute's (NCI's) funding mechanism for clinical trial cooperative groups. We expect that many of the recommendations from the 2010 Institute of Medicine report on the groups will coalesce in the new NCI funding guidelines, and that these guidelines will set the groups' scientific and operational parameters for years to come. The linked public comment is our collective attempt to publicly outline a set of principles we hope will guide the NCI as they move forward.
|
| |
S1007 RxPONDER trial will evaluate whether gene expression test can drive chemotherapy choice
[Apr. 26, 2011]
|
SWOG-led clinical trial S1007 will recruit 4,000 women to determine whether chemotherapy benefits patients with node positive breast cancer who have low to intermediate Oncotype DX® recurrence scores.
|
| |
S0421 closes early, finds no benefit from atrasentan added to chemo for advanced prostate cancer
[Apr. 21, 2011]
|
|
NCI-supported SWOG trial S0421 has closed early based on interim finding that atrasentan added to docetaxel and prednisone did not confer additional survival benefit to patients with hormone-refractory prostate cancer. Few patients remain on trial medication. Those that do should ask their doctor how to stop safely.
|
| |
Southwest Oncology Group becomes SWOG
[Apr. 6, 2011]
|
|
Noting that the regional focus of it's name no longer fit the national character of the network, the NCI clinical trial cooperative group formerly known as the Southwest Oncology Group announced it will now be simply 'SWOG.'
|
| |
| To News Releases Archive |
| |
| SWOG in the News |
| There are no current SWOG in the News items available. |
| To SWOG in the News Archive
|
| |
